06-11 Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders MT
06-11 Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions BU
06-11 Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions CI
06-10 Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 11:20 AM
06-09 Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing MT
06-05 Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference CI
06-05 Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference BU
06-03 Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 BU
06-02 Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing MT
06-01 Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy RE
06-01 Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy BU
06-01 Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy CI
05-29 Vertex Pharmaceuticals Incorporated Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-29-2026 09:00 AM
05-21 Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada DJ
05-21 Vertex Says Health Canada Accepts Suzetrigine Application for Review MT
05-21 Vertex Pharmaceuticals Announces New Drug Submission for Suzetrigine Accepted for Review by Health Canada CI
05-19 Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing MT
05-19 Vertex Pharmaceuticals Incorporated Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 02:35 PM
05-15 Daiwa Securities Adjusts PT on Vertex Pharmaceuticals to $555 From $561, Maintains Buy Rating MT
05-13 Declaration of Voting Results by Vertex Pharmaceuticals Incorporated CI
05-11 Vertex to Participate in Upcoming May Investor Conferences BU
05-07 Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany AQ
05-06 Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany BU
05-06 Vertex Pharmaceuticals Incorporated Signs Reimbursement Agreement for Casgevy in Germany CI
05-05 Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q) PU
No results match your criteria
  1. Stock Market
  2. Stocks
  3. VRTX Stock
  4. News Vertex Pharmaceuticals Incorporated
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!